Active Substance: Valsartan .
Overview
Welcome to Dwaey, specifically on DIOSTAR 160 mg page.
This medicine contains an important and useful components, as it consists of
Valsartan
is available in the market in concentration
Valsartan
Patients w/ renal artery stenosis, heart failure, aortic or mitral stenosis, severe Na and/or volume depletion. Renal and mild to moderate hepatic impairment. Lactation. Monitoring Parameters Monitor BP, electrolytes, renal function. Monitor serum K levels every dose increment and periodically thereafter.
Heart failure, Hypertension, Post myocardial infarction
Hypersensitivity; severe hepatic impairment, cirrhosis or biliary obstruction; primary hyperaldosteronism. Pregnancy (2nd and 3rd trimesters) and lactation.
>10% Dizziness (17%; heart failure),Increased blood urea nitrogen (BUN; 17%) 1-10% Hyperkalemia (4-10%),Dizziness (2-8%; hypertension),Hypotension (1-7%; heart failure),Fatigue (3%),Viral infection (3%),Neutropenia (2%),Syncope (>1%),Upper abdominal pain (>1%),Vertigo (>1%) Frequency Not Defined Headache,Cough (rare) Potentially Fatal: Blood dyscrasias (e.g. neutropenia).
4
Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.
May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Information not available